Phospho-FCGR2B (Tyr292) Antibody

What is the molecular target of Phospho-FCGR2B (Tyr292) antibodies?

Phospho-FCGR2B (Tyr292) antibodies specifically target the phosphorylated tyrosine residue at position 292 of the low-affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B, also known as CD32B). The target epitope typically consists of a phosphopeptide with the sequence I-T-Y(p)-S-L derived from human CD32B . This phosphorylation site is crucial for FCGR2B's inhibitory signaling functions in immune regulation.

How are Phospho-FCGR2B (Tyr292) antibodies produced and purified?

These antibodies are typically produced by immunizing rabbits with synthetic phosphopeptides conjugated to carrier proteins such as KLH (Keyhole Limpet Hemocyanin) . The production process involves:

• Immunization with the specific phosphopeptide sequence containing the Tyr292 phosphorylation site

• Collection and processing of antiserum

• Purification via affinity chromatography using epitope-specific phosphopeptides

• Critical removal of non-phospho specific antibodies using chromatography with non-phosphopeptide corresponding to the same site

This purification methodology ensures high specificity for the phosphorylated form of the protein.

What is the functional significance of FCGR2B Tyr292 phosphorylation in immune regulation?

FCGR2B is the only inhibitory member of the Fcγ receptor family and contains an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) in its cytoplasmic domain . Phosphorylation at Tyr292 is a critical regulatory event that:

• Enables recruitment of phosphatases such as SHIP1 to the inhibitory receptor

• Modulates ITAM-mediated activation signals when co-engaged with activating receptors

• Controls B cell activation thresholds and prevents autoimmune responses

• Regulates myeloid cell activation and inflammatory responses

FCGR2B was the first immune "checkpoint" defined, with mouse studies demonstrating its pivotal role in controlling autoreactive germinal center B cell activation and survival .

What are the validated applications for Phospho-FCGR2B (Tyr292) antibodies?

Based on the technical specifications from multiple manufacturers, these antibodies have been validated for several experimental applications with specific recommended dilutions:

K562 cells are frequently recommended as positive controls for Western blot applications .

How should researchers optimize Western blot conditions for detecting phosphorylated FCGR2B?

For optimal detection of phosphorylated FCGR2B (Tyr292):

• Sample preparation: Treat cells with phosphatase inhibitors immediately upon lysis. Evidence suggests pervanadate treatment (25 ng/mL, 72h) enhances phosphorylation signal, as demonstrated in MCF-7 and PC12 cell lines .

• Protein loading: Load 20-50 μg of total protein per lane for cell lysates.

• Blocking conditions: Use 5% BSA in TBST rather than milk (which contains phosphatases that can reduce signal).

• Antibody incubation: Apply primary antibody at 1:500-1:1000 dilution in 5% BSA/TBST overnight at 4°C.

• Detection method: Enhanced chemiluminescence (ECL) systems provide sufficient sensitivity for detection of phosphorylated FCGR2B proteins.

• Controls: Include both phosphatase-treated negative controls and pervanadate-treated positive controls to validate specificity .

What strategies can resolve non-specific binding issues with these antibodies?

When encountering non-specific binding:

• Peptide competition assay: Pre-incubate the antibody with excess phosphopeptide immunogen before application to demonstrate specificity. Non-phosphorylated peptide should not compete for binding.

• Cross-reactivity analysis: Verify reactivity using FCGR2B knockout or knockdown samples as negative controls.

• Optimization of blocking conditions: Increase BSA concentration to 5-10% and add 0.1% Tween-20 to reduce background.

• Stringent washing: Incorporate additional washing steps with higher salt concentration (up to 500 mM NaCl) in TBST.

• Affinity purification: Consider additional purification steps if non-specific binding persists, as different manufacturers employ varying purification protocols that can affect specificity .

How do researchers distinguish between phosphorylated FCGR2A and FCGR2B in experimental systems?

Distinguishing between phosphorylated FCGR2A and FCGR2B presents technical challenges due to their 95% sequence identity in extracellular domains . Methodological approaches include:

• Epitope specificity: The antibodies targeting phospho-Tyr292 of FCGR2B recognize a unique epitope (I-T-Y(p)-S-L) that differs from the corresponding region in FCGR2A .

• Cell type selection: Use B cells which primarily express FCGR2B but not FCGR2A for validation studies.

• Immunoprecipitation-based approach: Perform initial immunoprecipitation with isoform-specific antibodies followed by detection with phospho-specific antibodies.

• Mass spectrometry validation: For definitive identification, phosphopeptides can be analyzed by mass spectrometry to distinguish between the two receptors.

• Genetic validation: Utilize FCGR2B knockout models or selective knockdown approaches to confirm specificity of the phospho-signal .

What is the physiological context for FCGR2B Tyr292 phosphorylation in different cell types?

The phosphorylation of FCGR2B at Tyr292 exhibits cell type-specific regulatory patterns:

• B cells: Phosphorylation occurs during co-engagement with the B cell receptor (BCR), leading to recruitment of SHIP1 phosphatase and inhibition of BCR signaling. This is critical for maintaining B cell tolerance and preventing autoimmunity .

• Myeloid cells: In macrophages and dendritic cells, FCGR2B phosphorylation regulates inflammatory responses by modulating activating FcγR signaling and controlling cytokine production .

• Follicular dendritic cells (FDCs): FCGR2B is upregulated after immune complex stimulation and its phosphorylation state affects immune complex presentation to B cells, influencing germinal center responses .

• Cell-specific isoforms: FcγRIIB1 and FcγRIIB2 splice variants show differential expression and phosphorylation dynamics - FcγRIIB1 is phosphorylated by Lyn and Blk kinases in B cells, whereas FcγRIIB2 is phosphorylated primarily by Blk in myeloid cells .

How do Phospho-FCGR2B (Tyr292) antibodies perform in comparison with total FCGR2B antibodies for analyzing receptor activation states?

Comparative analysis reveals distinct advantages for phospho-specific antibodies:

What sample preparation protocols maximize phospho-epitope preservation for reliable detection?

Effective preservation of phosphorylated epitopes requires specific sample handling:

• Immediate stabilization: Harvest cells or tissues directly into lysis buffer containing phosphatase inhibitor cocktails (including sodium orthovanadate, sodium fluoride, and β-glycerophosphate).

• Temperature control: Maintain samples at 4°C throughout processing to minimize phosphatase activity.

• Denaturing conditions: Use SDS-containing buffers with rapid heating to 95-100°C to quickly denature phosphatases.

• Phosphatase stimulation/inhibition: For positive controls, treat cells with pervanadate (25 ng/mL for 72h) as demonstrated effective in MCF-7 and PC12 cells .

• Storage considerations: Aliquot lysates to avoid freeze-thaw cycles and store at -80°C rather than -20°C for long-term preservation of phospho-epitopes .

How can researchers validate phospho-specificity of signal detection in their experimental system?

Rigorous validation of phospho-specificity includes:

• Phosphatase treatment control: Treating duplicate samples with lambda phosphatase should eliminate signal from phospho-specific antibodies.

• Stimulation-dependent phosphorylation: Demonstrate increased signal following appropriate stimulation (e.g., BCR crosslinking in B cells).

• Phospho-null mutants: Express Tyr292Phe mutant FCGR2B constructs as negative controls for phospho-specific detection.

• Phospho-mimetic comparison: Compare detection with phospho-mimetic mutants (Tyr292Glu) to understand signal characteristics.

• Multiple detection methods: Confirm phosphorylation status using orthogonal techniques such as mass spectrometry or Phos-tag SDS-PAGE .

What are the critical factors for reproducibility when analyzing FCGR2B phosphorylation across different experimental models?

To ensure reproducible phosphorylation analysis:

• Standardized stimulation protocols: Define precise conditions for receptor stimulation, including concentrations, time points, and temperature.

• Cell line validation: Verify FCGR2B expression levels and isoform distribution (FcγRIIB1 vs. FcγRIIB2) in each model system.

• Genetic background considerations: Account for genetic polymorphisms that may affect FCGR2B signaling, particularly in human samples.

• Antibody lot validation: Test each new antibody lot against standard positive controls (e.g., pervanadate-treated K562 cells) .

• Quantification methods: Implement standardized quantification approaches, normalizing phospho-signal to total FCGR2B levels.

• Technical replicates: Perform at least three independent experiments with internal technical replicates to account for biological and technical variability .

How does FCGR2B Tyr292 phosphorylation influence therapeutic antibody efficacy in immunological disorders?

FCGR2B phosphorylation status significantly impacts therapeutic antibody effectiveness:

• Monoclonal antibody therapy modulation: The inhibitory signaling through phosphorylated FCGR2B can dampen therapeutic antibody efficacy by raising the threshold for immune cell activation.

• Fc engineering considerations: Therapeutic antibodies can be engineered with modified Fc regions to either enhance or reduce FCGR2B binding and subsequent phosphorylation, depending on the desired immunomodulatory effect.

• Predictive biomarker potential: Monitoring FCGR2B Tyr292 phosphorylation status may predict patient response to antibody therapies, particularly in autoimmune conditions.

• Combinatorial approaches: Inhibition of FCGR2B phosphorylation could synergize with therapeutic antibodies to enhance effector functions in cancer immunotherapy.

• Precision medicine applications: Polymorphisms affecting FCGR2B phosphorylation efficiency may explain variable therapeutic responses across patient populations .

What methodologies can determine the spatial and temporal dynamics of FCGR2B phosphorylation in live cells?

Advanced imaging and analytical techniques for studying phosphorylation dynamics include:

• Phospho-specific FRET sensors: Genetically encoded FRET-based biosensors incorporating the FCGR2B ITIM domain can monitor phosphorylation in real-time.

• Phospho-specific nanobodies: Cell-permeable phospho-specific nanobodies conjugated to fluorophores enable live-cell imaging of phosphorylation events.

• Lattice light-sheet microscopy: Combined with phospho-specific antibody fragments, this approach allows high-resolution 3D visualization of phosphorylation sites within membrane microdomains.

• Single-molecule tracking: Quantum dot-conjugated antibody fragments can track individual phosphorylated FCGR2B molecules in the membrane.

• Mass cytometry (CyTOF): Enables multiparametric analysis of phosphorylation events across heterogeneous cell populations with metal-conjugated phospho-specific antibodies .

How do differences in FCGR2B splice variants (FCGR2B1 vs. FCGR2B2) affect phosphorylation dynamics and detection strategies?

FCGR2B splice variants exhibit important differences in phosphorylation patterns:

• Variant-specific kinetics: FcγRIIB1 (predominantly in B cells) contains the C1 exon insertion that prolongs membrane retention, resulting in sustained phosphorylation signals. In contrast, FcγRIIB2 (in myeloid cells) is rapidly internalized, leading to transient phosphorylation events .

• Kinase preferences: Research indicates FcγRIIB1 is phosphorylated by both Lyn and Blk kinases, whereas FcγRIIB2 is primarily phosphorylated by Blk .

• Cellular localization differences: The C1 exon in FcγRIIB1 affects membrane microdomain localization, potentially altering accessibility for phospho-specific antibody detection.

• Detection strategy implications:

  • For FcγRIIB1: Cell surface staining techniques are appropriate due to prolonged membrane retention

  • For FcγRIIB2: Rapid fixation methods and membrane permeabilization are crucial to capture transient phosphorylation events

• Functional consequences: The extended phosphorylation of FcγRIIB1 contributes to its critical role in apoptosis of self-reactive B cells during somatic hypermutation .

What are the molecular mechanisms linking FCGR2B Tyr292 phosphorylation to downstream inhibitory signaling pathways?

The molecular signaling cascade initiated by Tyr292 phosphorylation involves:

• Phosphorylation-dependent recruitment: Upon phosphorylation, the ITIM domain (containing Tyr292) recruits the inositol phosphatases SHIP1 and SHIP2 via their SH2 domains with high affinity .

• Signaling complex formation: SHIP1 dephosphorylates phosphatidylinositol species, predominantly phosphatidylinositol 3,4,5-trisphosphate, and forms a complex with p62 Dok to create a highly active membrane-localized enzymatic complex .

• Pathway inhibition mechanisms:

  • Inhibition of Ras activation pathway

  • Decreased MAP kinase activation

  • Reduced PLCγ function leading to decreased PKC activation

  • Inhibition of the anti-apoptotic kinase Akt pathway

• Specificity determinants: The preferential recruitment of SHIP over SHP1/SHP2 phosphatases is determined by the SHIP SH2 domain's high affinity for the phosphorylated ITIM motif .

• Species-specific differences: Unlike mouse FCGR2B, human FCGR2B lacks the equivalent of Tyr326 (outside the ITIM) and an adjacent small deletion, resulting in failure to recruit Grb2 while still effectively recruiting SHIP1 .